Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEP-363856 in Generalized Anxiety Disorder
NCT07767903Phase 3Recruiting
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Aug 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
A Phase 3 trial of ulotaront in generalized anxiety disorder (GAD), sponsored by Otsuka Pharmaceutical Development & Commercialization. Started Aug 2026; status: recruiting.
02
Drugs
ulotaront
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT07767903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07767903.